Lithium is a first-line mood stabilizer for the treatment of bipolar affective disorder (BPAD). However, the efficacy of lithium varies widely, with a nonresponse rate of up to 30%. Biological response markers are lacking. Genetic factors are thought to mediate treatment response to lithium, and there is a previously reported genetic overlap between BPAD and schizophrenia (SCZ).
B ipolar affective disorder (BPAD) is a severe and often disabling psychiatric condition characterized by recurrent dysregulation of mood, with episodes of mania and depression. With an early onset and an estimated lifetime prevalence of 1% 1 to 4.4%, 2 BPAD is associated with high levels of personal impairment and high societal costs, accounting for 9.9 million years of life lived with disability worldwide, 3 increased all-cause mortality, and risk of suicide. 4 The possible causes of BPAD are complex, and both genetic and environmental factors contribute to its pathogenesis. 5 The estimated heritability of BPAD ranges from 60% to 85%, 6 and candidate gene 7 and genome-wide association studies (GWASs) [8] [9] [10] [11] [12] have successfully identified genetic loci implicated in the illness. Lithium's mood-stabilizing properties were discovered in 1949. 13 It has retained a status as the criterion standard mood stabilizer, 14, 15 possessing unique protective effects against both manic and depressive episodes, 16 as well as for suicide prevention. 17 Consequently, lithium is recommended as firstline maintenance treatment for BPAD by several clinical practice guidelines. [18] [19] [20] [21] However, there is significant interindividual variation between those who do and those who do not respond to treatment with lithium. About 30% of patients are only partially responsive, and more than one-fourth show no clinical response. 22 Although clinical studies report a combination of demographic and clinical characteristics as potential factors determining response to lithium treatment, 23 genetic factors also appear to be highly involved. 22, [24] [25] [26] So far, 3 GWASs have successfully identified single-nucleotide polymorphisms (SNPs) associated with treatment response to lithium in BPAD pointing to different genetic loci. 22, 26, 27 To improve our understanding of the molecular mechanisms underlying the therapeutic effects of lithium, alternative genomic approaches that can complement GWASs deserve consideration. One such approach is polygenic analysis, which quantifies the combined effects of genetic variants across the whole genome on a given clinical outcome, computed as a weighted summation of effect sizes of multiple independent polymorphisms. An accurate and successful polygenic model may assist early screening for disease risk, clinical diagnosis, and the determination of treatment response and prognosis. In the present study, we aimed to investigate whether patients with BPAD who had a high genetic susceptibility for schizophrenia (SCZ), expressed by their SCZ polygenic score (PGS), would respond better or more poorly to lithium compared with patients with BPAD who had a low PGS for SCZ. In addition, we set out to explore the genetic and molecular underpinnings of any identified association between SCZ and treatment response to lithium.
Several previous observations motivated this approach. First, there is increasing evidence for a substantial genetic overlap between BPAD and SCZ. The Psychiatric Genomics Consortium (PGC; http://www.med.unc.edu/pgc/) estimated a shared genetic variation between BPAD and SCZ of approximately 68%, which is the highest among all pairs of psychiatric diagnoses, 28 and several shared risk genes and shared biological pathways associated with both disorders have been identified. [29] [30] [31] Second, despite these genetic and molecular commonalities, lithium is not an effective medication for people with SCZ, 32 and increased SCZ trait loading in those with BPAD might be expected to be associated with poor treatment response to lithium. An earlier family study found an association between family history of SCZ and poor response to lithium. 33 Third, during acute episodes of illness, BPAD and SCZ are often difficult to distinguish clinically because of overlapping psychotic symptoms such as hallucinations, delusions, and disorganization, as well as some common behavioral disturbances such as irritability or anger. 34 Aiming to determine response to lithium, which could potentially confer advantages for patients and their treating physicians, 35 we sought to evaluate the aggregated outcome of genome-wide SNPs for SCZ on treatment response to lithium in patients with BPAD using a PGS approach that was based on the results of the largest SCZ GWAS to date. 36 Furthermore, to explore potential genetic and molecular drivers of any detected association, we carried out a cross-trait GWAS meta-analysis, combining the summary statistics from the largest available GWAS for both SCZ 36 and response to lithium.
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Methods
In the present study, conducted from 2008 to 2013, we first tested whether a PGS for SCZ is associated with treatment response to lithium in patients with BPAD; 2043 patients (79.0%) had BPAD type I and 543 (21.0%) had BPAD type II. 22 In a second step, we applied a cross-trait GWAS meta-analysis approach to identify individual genetic variants shared between SCZ and treatment response to lithium. In a third step, we characterized the genetic variants identified in the second step and explored the shared biological pathways underlying genetic susceptibility to SCZ and treatment response in BPAD. We built the PGS using the discovery GWAS outcome estimates Findings This genome-wide association study found an inverse association between genetic loading for schizophrenia risk variants and response to lithium in patients with bipolar affective disorder. Genetic variants in the HLA antigen region and the antigen presentation pathway point to the molecular underpinnings of schizophrenia and lithium treatment response.
Meaning For patients with bipolar affective disorder, assessment of a polygenic load for schizophrenia risk variants, in conjunction with clinical data, may assist in determining whether they would respond to lithium treatment.
that met genome-wide significance in the meta-GWAS were subsequently analyzed for biological context using the Ingenuity Pathway Analysis platform (IPA; QIAGEN [http://www .ingenuity.com]). This study used consortium data through an international collaboration. The University of Heidelberg Ethics Committee provided central ethics approval for the consortium. Written consent was obtained from each patient according to the study protocols of the participating cohorts.
Target Outcome
Lithium treatment outcome was assessed using the Retrospective Criteria of Long-term Treatment Response in Research Subjects With Bipolar Disorder scale, also known as the ALDA scale. 38, 39 The ALDA scale quantifies symptom improvement over the course of treatment (A score; range, 0-10), which is then weighted against 5 criteria (B score) that assess confounding factors, each scored 0, 1, or 2. The total score is calculated by subtracting the total B score from the A score, with negative scores set to zero. 22 We employed a categorical and a continuous outcome for response to lithium. The categorical (ie, good vs poor) response to lithium was defined based on the total score as a cutoff score of 7, in which patients with a total score of 7 or higher were categorized as responders. The ALDA score on subscale A was used as a continuous outcome after excluding individuals with a total B score greater than 4 or who had missing data on the totals of ALDA subscale A or B.
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Polygenic Scoring
Quality-controlled SNPs were clumped for linkage disequilibrium based on GWAS association P value-informed clumping using r 2 = 0.1 within a 250-kilobase (kb) window to create an SNP set in linkage equilibrium using PLINK software 40 run on Linux (plink-clump-p1 1-clump-p2 1-clump-r2 0.1-clump-kb 250). Then, the SNPs up to 10 P value thresholds (<1 × 10 −4 , <1×10 −3
, <.01, <.05, <.1, <.20, <.30, <.40, <.50, and <1.0) were selected to compute the SCZ PGSs in the ConLi + Gen sample.
A genome-wide weighted SCZ PGS for each participant was calculated at each P value threshold as the sum of independent SNPs genotype dosage (from 0 to 2) of the reference allele in the ConLi + Gen genotype data, multiplied by effect sizes on the SCZ GWAS for the reference allele, estimated as log (OR) divided by the total number of SNPs in each threshold.
Statistical Analyses
Statistical analysis was performed from September 2016 to February 2017. We applied PGS association analyses, cross-trait meta-GWAS, and IPA of the cross-trait findings.
PGS Association Analysis
Once the PGSs were constructed, the association of the PGSs at each threshold P value with treatment response to lithium was evaluated using regression models. While a binary logistic regression was implemented for the categorical outcome (response vs nonresponse), a linear regression was applied to treatment response to lithium on the continuous scale. Using the PGS at the most significant threshold (P <5×10 −2 ), we divided the study samples into 10 deciles, ranging from the lowest polygenic load (first decile) to the highest polygenic load (10th decile). We then compared patients with BPAD with a lower polygenic load (first to ninth deciles) for SCZ with patients with the highest polygenic load (10th decile) to quantify the association of SCZ polygenic load with lithium treatment outcomes.
To control for confounding factors, the PGS association analyses were adjusted for the covariates of age, sex, genotyping platforms, and 7 principal components. The analyses were performed using R (R Foundation for Statistical Computing) and PLINK, version 1.9, for Linux. 40 The accuracy of determining factors and the percentage of variance in lithium response accounted for by the PGS at each P value threshold were estimated as the variance explained by the full model including each PGS and covariates minus the variance explained by the model including only covariates. Statistical significance was determined at P < .05 after adjusting for covariates.
Cross-trait Meta-analysis of GWASs Biologically, a significantly associated PGS implies that genetic factors influencing the 2 traits are overlapping. Thus, further analyses were performed to identify genetic polymorphisms that are likely to increase the susceptibility to SCZ and also influence treatment response to lithium in patients with BPAD. We performed cross-trait meta-analyses by combining the summary statistics for GWAS on lithium response from the ConLi + Gen 22 and GWAS on SCZ from the PGC. 36 Ingenuity Pathway Analysis To characterize the potential biological significance of the SNPs discovered from the cross-trait meta-analyses, we performed analyses using IPA (eAppendix in the Supplement).
Results
Sample Characteristics
A total of 3193 patients with BPAD who had undergone lithium treatment and had available genotype and clinical data participated in the study. After quality control, 2586 patients remained for analysis, of whom 2366 were of European ancestry and the rest Asian. The mean (SD) age of all the patients combined was 47.2 (13.9) years and 1478 (57.2%) were female. A total of 704 patients (27.2%) had a good response to lithium treatment (ALDA scale score ≥7). The mean (SD) ALDA scale score for all participants was 4.1 (3.2) ( Table 1) .
Association of SCZ PGS With Treatment Response to Lithium in Patients With BPAD
At the most significantly associated P value threshold (P <5×10 −2 ), the PGS for SCZ was strongly associated with Table 2 shows the ORs for the association between treatment response to lithium in BPAD and SCZ PGS in deciles, comparing the response status of patients in the low polygenic load categories (first to ninth deciles) with the response status of patients in the highest polygenic load category for SCZ (10th decile). Patients with BPAD who carry a lower polygenic load for SCZ have higher odds of favorable treatment response to lithium compared with patients carrying a high polygenic load; the OR of favorable treatment response decreased as the genetic load for SCZ increased, ranging from an OR of 3.46 (95% CI, 1.42-8.41) at the first decile to an OR of 2.03 (95% CI, 0.86-4.81) at the ninth decile, compared with the reference SCZ PGS at the 10th decile (Table 2 ). There was a significant linear trend in the odds of treatment response to lithium across the deciles (Figure, B) .
Cross-trait Meta-analysis of GWAS for Lithium Treatment Response in BPAD and of GWAS for SCZ
Subsequent to the PGS analysis, we performed an SNP-based cross-trait meta-analysis by combining the summary statistics for the GWASs on SCZ and treatment response to lithium in the categorical outcome and on SCZ and treatment response to lithium in the continuous outcome. This meta-analysis yielded 15 loci with P values below the genome-wide significance level (P <5×10 −8 ). To characterize the functional implications of these loci, we undertook IPA using query gene inputs generated from the results of the cross-trait and expression quantitative trait loci analyses (http://www.genenetwork.org/webqtl/main.py; http: //www.braineac.org/;eT able1intheSupplement). The IPA found significantly represented canonical pathways, with the top 5 being antigen presentation pathway, OX40 signaling pathway, autoimmune thyroid disease signaling, Cdc42 signaling, and B-cell development (eTable 2 in the Supplement). These pathways were predominantly identified on the basis of several HLA antigen genes: HLA-A (OMIM 142800), HLA-DMA (OMIM 142855), HLA-DMB (OMIM 142856), HLA-DOB (OMIM 600629), HLA-DPB1 (OMIM 142858), HLA-F (OMIM 143110), HLA-G (OMIM 142871), PSMB9 (OMIM 177045), and TAP2 (OMIM 170261).
The IPA revealed 2 relevant functional networks (eTable 3intheSupplement). As shown in eFigure 3A and B in the Supplement, the top 2 networks indicate that tumor necrosis factor (TNF), interleukin 4 (IL-4), and interferon-gamma (IFNγ) might represent important functional molecular nodes in the interaction between response to lithium and SCZ.
Discussion
The present study reports 2 main findings. First, using PGS, we demonstrate that there is an inverse association between genetic loading for SCZ risk variants and long-term therapeutic response to lithium in patients with BPAD on the categorical outcome of the ALDA scale. Second, we show in the crosstrait meta-GWAS and IPA that genetic variants in the HLA antigen region, the antigen presentation pathway, and inflammatory cytokines such as TNF, IL-4 and IFNγ could play a biological role in treatment response to lithium in BPAD.
These findings are consistent with previous clinical and epidemiologic studies of response to lithium. Lithium is not an effective medication for people with SCZ spectrum disorders.
32,43 Moreover, lithium may be deleterious for patients with SCZ because of their greater liability to developing lithium-induced neurotoxic effects even at modest doses and blood levels. 43, 44 The severity of psychotic symptoms in patients with BPAD was found to be inversely associated with treatment response to lithium. 45 Similarly, slow resolution of psychosis in response to lithium treatment during acute manic episodes has been shown to be associated with poorer overall response to the drug. 46 Among patients with BPAD, those with a family history of SCZ show poorer response to lithium compared with those with a family history of BPAD. 47 Our findings may provide insight into the genetic architecture underlying these clinical observations. a Total ALDA scale score of 7 or higher was defined as good response.
b Participants with total B score higher than 4 or who had missing data on the total scores on ALDA subscale A or B were excluded.
In the SCZ to lithium response cross-trait GWAS metaanalyses, 15 genetic loci located within protein-coding genes that appear to have overlapping outcomes on SCZ risk and treatment response to lithium in BPAD were identified. Only 1 of these genes, type 1 adenylyl cyclase (ADCY1 [OMIM 103072]), had previously been directly implicated in genetic studies of both SCZ 48 and treatment response to lithium.
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Both the most significant finding of the cross-trait GWAS and the SNPs from the post-GWAS functional analyses suggest that the HLA antigen system could be implicated in genetic susceptibility to SCZ and treatment response to lithium. The HLA antigen region is the most robust genetic finding in SCZ 49 and could be marking a SCZ-type pathogenesis that is associated with nonresponse to lithium. Although the extensive linkage disequilibrium in the HLA antigen region, and the fact that non-HLA antigen genes are embedded within it, could compromise the biological precision of our pathway analysis, some previous studies have linked HLA antigen surface protein composition to responsiveness to lithium in patients with BPAD. 50-52 Lithium exposure of human monocytes and mouse Whether these outcomes are in some way compromised by the decreased neuronal complement component 3 expression that is associated with SCZ risk variants in the HLA antigen region, 49 and whether such mechanisms play a role in the clinical efficacy of lithium, needs to be explored in future studies. Furthermore, network analyses of genes from our meta-GWAS findings implicated TNF, IL-4, and IFNγ as central functional nodes, suggesting that the negative interaction between response to lithium and genetic predisposition for SCZ could be mediated by mechanisms implicating these inflammatory cytokines; this finding is also supported by a growing body of evidence describing aberrant inflammatory processes in patients with a first episode of psychosis 56 and SCZ.
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Previous studies have reported modulatory outcomes of lithium treatment on these cytokines and underscore the possibility that mechanisms involving inflammatory cytokines might play a role in mediating the therapeutic outcomes of lithium in patients with BPAD.
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Our findings have important implications for the treatment of BPAD and for future research. We show for the first time, to our knowledge, that genetic characterization has the potential to aid the stratification of patients with BPAD into those who respond and those who do not respond to lithium, prior to initiation of treatment. Our study also supports the idea that responsiveness to lithium could represent a true psychiatric endophenotype beyond current nosologic descriptions.
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The findings underscore the importance of careful assessments of patients' family psychiatric histories in the context of treatment selection. In schizoaffective disorder, which remains challenging clinically owing to a lack of specific effective treatments, 67 determination of SCZ PGS might aid the choice of mood-stabilizing agents. To achieve full clinical translation, PGS analyses could be combined with other biological and clinical factors in prognostic algorithms.
Limitations
This study has some limitations. First, the polygenic load for SCZ accounted for only a modest percentage (approximately 1%) of the observed variation in lithium treatment response in patients with BPAD. Although this finding is in line with previous reports on the outcomes of PGSs on complex clinical phenotypes such as SCZ and BPAD, 68 the significance of this finding at clinical and population levels needs to be further explored. Second, response to lithium in our study was assessed using the ALDA scale, which is a retrospective measure. To substantiate our findings further, prospective studies are required that can prospectively measure clinical responses to lithium. Third, while our strategy for exploring the biological context of our genetic findings can point toward avenues for future research, it is not designed to provide definitive mechanistic answers. Hypothesis-driven experiments are required to follow up on these leads. 
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Abbreviations: A1, effect allele; A2, another allele; BPAD, bipolar affective disorder; BP, position in base pairs at Human Genome Assembly build 37; Chr, chromosome; GWAS, genome-wide association study; SCZ, schizophrenia; SNP, single-nucleotide polymorphism; +, increased susceptibility to SCZ or positive effect on lithium response; -, decreased susceptibility to SCZ or negative effect on lithium response.
c Effect direction is the effect of the SNPs on schizophrenia and treatment response to lithium oriented to the effect allele (A1). Nearest genes were based on The Reference Sequence genes (build 37).
d Categorical.
e Continuous.
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Conclusions
We demonstrated for the first time that lower SCZ loading is associated with better response to lithium in patients with BPAD. Follow-up functional analyses implicate genes that code for the immune system, including the HLA antigen complex and inflammatory cytokines. For future clinical translation, a high genetic loading for SCZ risk variants could be used in conjunction with clinical parameters to determine the likelihood of nonresponse to lithium treatmentinBPAD. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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We thank all the patients who participated in the study, and we appreciate the contributions of the clinicians, scientists, research assistants, and study staff who helped in the patient recruitment, data collection, and sample preparation of the studies. We are also indebted to the members of the ConLi The ConLi + Gen Consortium (www.ConLiGen.org) is an initiative by the National Institute of Mental Health (NIMH) and the International Group for the Study of Lithium-Treated Patients (IGSLI) (www.IGSLI.org) that was established with the aim of discovering genetic variants responsible for lithium treatment response in BPAD. 1 The ConLi + Gen study involved patients with BPAD from Europe, South America, USA, Asia, and Australia 2 who had been treated with lithium at some stage since diagnosis. The first GWAS based on this initiative was published in 2016. 2 For the current study, genetic and clinical data collected from 2,586 patients with BPAD who were part of the ConLi + Gen consortium were analyzed.
1,2 A series of quality control procedures were implemented on the genotype data before and after imputation as described below.
Genotyping and quality control
The genome-wide genotypes, as well as clinical and demographic data, were collected by 22 participating sites. Quality control (QC) procedures were implemented using PLINK. 3 Samples with low genotype rates <95%, sex inconsistencies (X-chromosome heterozygosity), and genetically related individuals were excluded. We also excluded SNPs that had a poor genotyping rate (<95%), an ambiguity (A/T and C/G SNPs), a low minor allele frequency (MAF<1%), or that showed deviation from Hardy-Weinberg Equilibrium (p<10 -6 ).
Imputation
The genotype data passing QC were imputed on the Michigan server 4 (https://imputationserver.sph.umich.edu) separately for each genotype platform using the 1000 Genomes Project Phase 3 (Version 5) reference panel. During the imputation process, we used the European reference panel for all the samples except for those from Japan and Taiwan, for which the East Asian reference population was used. After excluding the lowfrequency SNPs (MAF<10%); low-quality variants (imputation INFO < 0.9); and indels, the imputed dosages were converted to best guess genotypes. The subsequent polygenic analyses were performed using the best guess genotypes.
Discovery GWAS summary data
The PGSs were calculated using the approach previously described by the International Schizophrenia Consortium. 5 This method requires discovery and target datasets. The discovery data, which refers to the GWAS summary statistics-effect sizes (beta, a log of odds ratio), were obtained from a previously published SCZ GWAS 6 that was publicly available for download by the Psychiatric Genomics Consortium (PGC) http://www.med.unc.edu/pgc/, accessed on March 18, 2017.
Target outcome
Lithium treatment response in BPAD was defined for patients who had received lithium for a minimum of 6 months. Lithium treatment outcome was assessed using the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale, also known as the ALDA scale. 7, 8 The ALDA scale is a well-validated tool to rate symptom improvements after treatment with lithium in BPAD, and it has shown excellent inter-rater reliability. 9 The ALDA scale quantifies symptom improvement over the course of treatment (A score, range 0-10), which is then weighted against five criteria (B score) that assess confounding factors, each scored 0, 1, or 2. The total score is calculated by subtracting the total B score from the A score, and negative scores are set to zero. 2 We developed two main outcomes for lithium response (categorical and continuous outcome). The categorical (i.e., good versus poor) response to lithium in BPAD was defined based on the total score as a cut-off score of 7, in which patients with a total score of 7 or higher were categorized as "responders". The ALDA score on subscale A was used as a continuous outcome after excluding individuals with a total B score greater than 4 or who had missing data on the total scores of ALDA subscale A or B.
2 In addition to the ALDA scale scores, information on covariates such as age and gender was collected, and further details can be found in an earlier publication.
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Polygenic scoring
Quality-controlled SNPs were clumped for linkage disequilibrium based on GWAS association p-value informed clumping using r 2 = 0.1 within a 250-kb window to create a SNP-set in linkage equilibrium using PLINK software run on Linux (plink --clump-p1 1 --clump-p2 1 --clump-r2 0.1 --clump-kb 250). Then, the SNPs at ten p-value thresholds (<1x10 Gen sample. The major histocompatibility complex region was excluded from the PGS calculation because of its complex linkage disequilibrium structure. A genomewide weighted SCZ PGS for each participant was calculated at each p-value threshold (P T ) as the sum of independent SNPs genotype dosage (from 0 to 2) of the reference allele in the ConLi + Gen genotype data, multiplied by SCZ GWAS effect sizes for the reference allele, estimated as log (OR) divided by the total number of SNPs in each threshold.
Statistical analyses
For statistical analyses, we applied PGS association analyses, cross-trait meta-GWAS, and Ingenuity Pathway Analysis (IPA) of the cross-trait findings. The details for each analysis are described below.
Polygenic score association analysis
Once the PGSs were constructed, the association of the PGSs at each P T and lithium treatment response was evaluated using regression models. While a binary logistic regression was implemented for the categorical outcome (response versus non-response), a linear regression was applied to lithium treatment response on the continuous scale. Using the PGS at the most significant threshold (P T <5x10 -2 ), we divided the study samples into ten deciles (1 st to 10 th ), ranging from the lowest polygenic load (1 st decile) to the highest polygenic load (10 th decile). The most significant threshold refers to the P T at which the PGS for SCZ and lithium treatment outcomes were most strongly associated (i.e., the smallest p-value). Using binary logistic and linear regression modeling, we compared BPAD patients with lower polygenic load (1 st to 9 th deciles) for SCZ with patients with the highest polygenic load (10 th decile), to quantify the effect of SCZ polygenic load on lithium treatment outcomes. Associations were considered significant at p<0.05.
The PGS association analyses were adjusted for the covariates age, gender, genotyping platform, and 7 principal components (PCs) calculated in PLINK. The analyses were performed using R for Statistical Computing and PLINK 1.9 for Linux. 3 Prediction accuracy, the percentage of variance in lithium response accounted by for the PGS at each P T , was 1) Westra et al 13 at FDR<0.05 http://genenetwork.nl/bloodeqtlbrowser/, 2) Almanac (Braineac) 14 at p<1x10 -5 http://www.braineac.org/, and 3) Genotype-Tissue Expression (GTEx) data release V6p (dbGaP Accession phs000424.v6.p1) accessed from the GTEx Portal on February 8, 2017, at https://www.gtexportal.org/home/. Finally, the combined list of hGenes and eGenes was used as input into the IPA software after removing gene duplicates. IPA compares the proportion of input genes mapping to a biological pathway to the reference genes list in the ingenuity databases. The significance of the overrepresented canonical pathways and functional networks is determined using the right-tailed Fisher's exact test and later adjusted for multiple testing using the BenjaminiHochberg (BH) method. 15 Significant results were determined at BH adjusted P-value <0.01. Legend: eGenes represents the list of genes from the expression quantitative trait loci (eQTL) lookup whose expression was associated with each of the gSNPs and tagSNPs. The genes hosting the gSNPs and tagSNPs denotes the list of hosting genes (hGenes). gSNPs: significant loci from the meta-GWAS. tagSNPs: SNPs in high linkage disequilibrium (LD: r 2 >0.5) and within a + 500-kb region with the gSNPs. eFigure 1. Scatter plot that assesses the linearity between the PGS for SCZ and total score on the ALDA subscale A
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Legend:
The −log10 (cross-trait p-value) is plotted against the physical position of each SNP on each chromosome. The threshold for genome-wide significance (cross-trait p-value<5x10 -8 ) is indicated by the red dotted horizontal line.
